Idsk -- MILAN (EGMN) – Tivozanib, an investigational agent, is not only active in the treatment of renal cell carcinoma, but is also associated with minimal “off target” toxicity, according to phase II study findings.
Idsk -- MILAN (EGMN) – Tivozanib, an investigational agent, is not only active in the treatment of renal cell carcinoma, but is also associated with minimal “off target” toxicity, according to phase II study findings.
